Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Theodore F, Logan"'
Autor:
Axel Hauschild, Claus Garbe, Omid Hamid, Philip Friedlander, Janice M. Mehnert, Wendy Snyder, Parminder Singh, Frances A. Collichio, Igor Puzanov, Merrick I. Ross, Min Yi, Mohammed M. Milhem, John A. Glaspy, Céleste Lebbé, Jason Chesney, Theodore F. Logan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background This is the first randomized trial evaluating an oncolytic virus with an immune checkpoint inhibitor in advanced melanoma. Improved objective response rate (ORR) was observed for T-VEC plus IPI compared to IPI alone (39% vs. 18%; OR 2.9; 9
Autor:
Céleste Lebbé, Merrick I. Ross, Axel Hauschild, Theodore F. Logan, Robert H.I. Andtbacka, John A. Glaspy, Philip Friedlander, Claus Garbe, Jason Chesney, Omid Hamid, Howard L. Kaufman, Parminder Singh, Jenny J. Kim, Frances A. Collichio, Jennifer Gansert, Mohammed M. Milhem, Lisa Chen, Igor Puzanov
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 17
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolyti
Autor:
Robert S. Alter, J. Thaddeus Beck, Monika Joshi, Earle F. Burgess, David R. Shaffer, Mayer Fishman, Ralph J. Hauke, Nicholas J. Vogelzang, Martin H. Voss, Nauman Moazzam, Xiaosha Zhang, Chad E. Glasser, Elizabeth R. Plimack, Rupal S. Bhatt, Michael B. Atkins, Theodore F. Logan, Rahul A. Parikh, Matthew L. Sherman, Brian I. Rini
Publikováno v:
Cancer
BACKGROUND In a prior open-label study, the combination of dalantercept, a novel antiangiogenic targeting activin receptor-like kinase 1 (ALK1), plus axitinib was deemed safe and tolerable with a promising efficacy signal in patients with advanced re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0196483f823f2190dadaf46fe5ecb04c
https://europepmc.org/articles/PMC6602847/
https://europepmc.org/articles/PMC6602847/
Autor:
S Dropcho, Naomi B. Haas, Roberto Pili, Hao Liu, Vivek Narayan, Lina M Sego, Theodore F. Logan, Sandra K. Althouse, Nabil Adra, Nur P. Damayanti, Paul Monk
Publikováno v:
Journal of Clinical Oncology. 38:5064-5064
5064 Background: Immunosuppressive regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) limit the efficacy of immunotherapies. We have previously reported that the HDAC inhibitor entinostat has synergistic antitumor effect in combi
Autor:
Jeffrey S. Weber, Theodore F. Logan, Elmer Berghorn, Jeffrey A. Sosman, Suresh G. Nair Md, Donald P. Lawrence, Leslie A. Fecher, Christine Horak, George Kong, Lynn M. Schuchter, Craig L. Slingluff, Geoff Gibney, Joel Jiang, F. Stephen Hodi, Elizabeth I. Buchbinder, Mary Ruisi, Ryan J. Sullivan
Publikováno v:
The Lancet. Oncology. 17(7)
Summary Background Concurrent administration of the immune checkpoint inhibitors nivolumab and ipilimumab has shown greater efficacy than either agent alone in patients with advanced melanoma, albeit with more high-grade adverse events. We assessed w
Autor:
Herbert J. Zeh, Paul Monk, Leonard Joseph Appleman, David M. Friedland, Xiaoyan Liang, Theodore F. Logan, David F. McDermott, Jodi K. Maranchie, Rahul Atul Parikh, Daniel P. Normolle, Michael T. Lotze, Lisa H. Butterfield, Marc S. Ernstoff, Thomas Olencki
Publikováno v:
Journal of Clinical Oncology. 36:4573-4573
4573Background: Aldesleukin (recombinant human interleukin-2, IL-2) has been an FDA-approved treatment for mRCC since 1992 with a 5-10% rate of durable complete response. Hydroxychloroquine (HCQ) i...
Autor:
Jon M. Richards, Robert Weber, Jeffrey A. Sosman, Peter Hersey, William H. Sharfman, John M. Kirkwood, Manuela Buzoianu, Agop Y. Bedikian, Steven J. O'Day, Luz Hammershaimb, Rene Gonzalez, Theodore F. Logan
Publikováno v:
Cancer. 116:1526-1534
BACKGROUND: The alpha v beta 3 (αvβ3) integrin is involved in intracellular signaling regulating cell proliferation, migration, and differentiation and is important for tumor-induced angiogenesis. METHODS: This phase 2, randomized, open-label, 2-ar
Autor:
Bruce G. Redman, Elizabeth R. Plimack, Ulka N. Vaishampayan, Theodore F. Logan, Kim Margolin, David F. McDermott, Timothy M. Kuzel, Michael R. Harrison, Robert J. Motzer, Hans J. Hammers, Ian M. Waxman, Brian I. Rini, Alexandre Lambert, Saby George, Harry A. Drabkin
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(13)
Purpose Nivolumab is a fully human immunoglobulin G4 programmed death–1 immune checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the antitumor activity, dose-response relationship, and safety of nivolu
Autor:
Kim Margolin, Theodore F. Logan, Janice P. Dutcher, Geoff Weiss, Michael B. Atkins, James W. Mier, Joseph I. Clark, Frederick R. Aronson, Jeffrey A. Sosman
Publikováno v:
Medical Oncology. 18:209-220
The Cytokine Working Group (CWG) was initially established in 1986 as the Extramural IL-2/LAK Working Group. With funding from the National Cancer Institute (NCI), the CWG was mandated to confirming data regarding the efficacy of the high-dose interl
Autor:
Margaret A. Marshall, Amy P. Abernethy, Michael S. Gordon, John A. Glaspy, Bo Huang, Jesus Gomez-Navarro, Antoni Ribas, Theodore F. Logan, David H. Lawson, Bartosz Chmielowksi, Diana Gerhardt, Rene Gonzalez, Karl D. Lewis, Erjian Wang, Poe Hirr Hsyu, Jason Chesney
Publikováno v:
Journal of Translational Medicine, Vol 10, Iss 1, p 236 (2012)
Journal of Translational Medicine
Ribas, Antoni; Chesney, Jason A; Gordon, Michael S; Abernethy, Amy P; Logan, Theodore F; Lawson, David H; et al.(2012). Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. Journal of Translational Medicine, 10(1), 236. doi: http://dx.doi.org/10.1186/1479-5876-10-236. Retrieved from: http://www.escholarship.org/uc/item/08b3211x
Journal of Translational Medicine
Ribas, Antoni; Chesney, Jason A; Gordon, Michael S; Abernethy, Amy P; Logan, Theodore F; Lawson, David H; et al.(2012). Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. Journal of Translational Medicine, 10(1), 236. doi: http://dx.doi.org/10.1186/1479-5876-10-236. Retrieved from: http://www.escholarship.org/uc/item/08b3211x
Background CTLA4 blocking monoclonal antibodies provide a low frequency but durable tumor responses in patients with metastatic melanoma, which led to the regulatory approval of ipilimumab based on two randomized clinical trials with overall survival